Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies

      Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies

- Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data
Presented at the International Liver Congress 2013 -

PR Newswire

NORCROSS, Ga., April 29, 2013

NORCROSS, Ga., April 29, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ:
GALT), the leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today released data that was presented on April 27,
2013 at the International Liver Congress in Amsterdam, The Netherlands. The
data were generated by the laboratory of Dr. Scott Friedman of the Icahn
School of Medicine at Mount Sinai, a world renowned investigator and expert on
liver fibrosis. GR-MD-02 and GM-CT-01, drugs that inhibit galectin proteins,
were found to reverse the most advanced stage of liver fibrosis, called
cirrhosis, in experimental animals given toxin-induced cirrhosis.

"The findings of these experiments show that the anti-galectin drugs had a
robust effect on cirrhosis, including reversal of tissue architectural changes
in the liver that result from fibrosis as well as reduction in portal
hypertension, an important pathophysiological effect of cirrhosis," said Dr.
Friedman, Dean for Therapeutic Discovery and Chief, Division of Liver Diseases
at the Icahn School of Medicine at Mount Sinai. "The experimental design of
these studies provided a very high hurdle for any drug to show effectiveness,
and yet both GR-MD-02 and GM-CT-01 passed the test. These drugs are excellent
candidates for evaluation in human cirrhosis."

"We are gratified that one of the most prominent investigators in the world
has shown that our galectin inhibitors were effective in experimental
cirrhosis, the most severe form of liver fibrosis, for which there are no
currently approved medical therapies," said Dr. Peter G. Traber, President,
Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics.
"Along with the multiple studies we have presented on liver fibrosis from
fatty liver disease, these findings provide added confidence for the potential
of this approach in studies of human liver fibrosis and cirrhosis."

The data presented at the International Liver Congress which is sponsored by
the European Association for the Study of the Liver (EASL) are posted on the
Company website at Rats were treated with a liver toxin
which produced fibrosis that replaced over 25% of the liver tissue and
resulted in architectural changes consistent with cirrhosis. While continuing
to treat with the liver toxin, rats were treated with either a placebo or four
weekly injections of either GR-MD-02 or GM-CT-01. The livers were reviewed by
a highly qualified liver pathologist who was unaware of the treatments that
the animals had received. Both drugs significantly reduced the amount of
fibrotic tissue, and most importantly, reversed the histological findings of
cirrhosis. Additionally there was a reduction in the blood pressure in the
blood system supplying the liver (portal pressure) in the treated animals.
Cirrhosis and portal hypertension are the primary abnormalities that lead to
complications and death in humans with liver fibrosis. Galectin previously
announced initiation of a Phase 1 clinical trial of GR-MD-02 in patients with
fatty liver disease (NASH, non-alcoholic steatohepatitis) with advanced
fibrosis which is expected to begin enrolling patients in May 2013

About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at

Forward Looking Statements
This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.

SOURCE Galectin Therapeutics

Contact: Galectin Therapeutics Inc., Peter G. Traber, Chief Executive Officer,
(678) 620-3186,
Press spacebar to pause and continue. Press esc to stop.